Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
4
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
4
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
4
×
merck
4
×
national
national blog main
national top stories
new york blog main
4
×
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
4
×
alzheimer's disease
cancer
cancer immunotherapy
diagnostics
eli lilly
gilead sciences
novartis
pfizer
amgen
What
bio
drug
roundup
acquisitions
biggest
ceo
companies
nash
news
albert
approval
approved
biogen’s
biopharmaceutical
bourla
build
buy
company
company’s
convo
crispr
daniel
debut
digital
disease
dyne’s
earlier
epidemic
failures
fatty
fda
frenzied
future
gilead
growing
imports
known
led
littered
liver
Language
unknown
unset
Current search:
abbvie
×
merck
×
" life sciences "
×
" new york blog main "
×
" wisconsin top stories "
×
deals
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More